We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01262651
Recruitment Status : Completed
First Posted : December 17, 2010
Last Update Posted : July 6, 2016
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.

Brief Summary:

This 9-week study will aim to determine the efficacy, safety and tolerability of Sativex® (Nabiximols) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in patients with advanced cancer.

Eligible patients will not be required to stop any of their current treatments or medications.

Condition or disease Intervention/treatment Phase
Pain Advanced Cancer Drug: Sativex® Drug: Placebo (GA-0034) Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 397 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.
Study Start Date : November 2010
Primary Completion Date : June 2015
Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: Sativex®
Sativex oromucosal spray. 100 μl administered twice daily up to a maximum of 10 sprays per day.
Drug: Sativex®
Other Name: Nabiximols
Placebo Comparator: Placebo (GA-0034)
Placebo oromucosal spray. 100 μl administered twice daily up to a maximum of 10 sprays per day.
Drug: Placebo (GA-0034)

Primary Outcome Measures :
  1. The primary endpoint is the percent improvement from baseline to the end of treatment in NRS average pain score. [ Time Frame: 5 weeks ]

Secondary Outcome Measures :
  1. Change from baseline in mean NRS average pain [ Time Frame: 5 weeks ]
  2. Change from baseline in mean NRS worst pain [ Time Frame: 5 weeks ]
  3. Change from baseline in mean Sleep Disruption NRS [ Time Frame: 5 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria (abbreviated):

  • The patient has advanced cancer for which there is no known curative therapy
  • The patient has a clinical diagnosis of cancer related pain, which is not alleviated with their current optimized opioid treatment
  • The patient is receiving an optimized maintenance dose of Step III opioid therapy, preferably with a sustained release preparation, but also allowing a regular maintenance dose of around the clock use of immediate release preparations
  • The patient is receiving a daily maintenance dose Step III opioid therapy of less than or equal to a total daily opioid dose of 500 mg/day of morphine equivalence (including maintenance and break-through opioids)
  • The patient is using no more than one type of break-through opioid analgesia

Exclusion Criteria (abbreviated):

  • Have any planned clinical interventions that would affect their pain (e.g., chemotherapy or radiation therapy where, in the clinical judgment of the investigator, these would be expected to affect pain)
  • The patient is currently using or has used cannabis or cannabinoid based medications within 30 days of study entry and is unwilling to abstain for the duration of the study
  • Has experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the patient at risk of a clinically significant arrhythmia or myocardial infarction
  • Has significantly impaired renal function
  • Has significantly impaired hepatic function
  • Female patients of child-bearing potential and male patients whose partner is of child-bearing potential, unless willing to ensure that they or their partner use effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for 3 months thereafter (however, a male condom should not be used in conjunction with a female condom as this may not prove effective)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01262651

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States, 85018
Phoenix, Arizona, United States, 85028
United States, California
El Cajon, California, United States, 92020
Gilroy, California, United States, 95020
United States, Florida
Brandon, Florida, United States, 33511
Daytona Beach, Florida, United States, 32117
Holiday, Florida, United States, 34691
Jacksonville, Florida, United States, 32257
Lynn Haven, Florida, United States, 32444
Miami, Florida, United States, 33143
Stuart, Florida, United States, 34994
United States, Georgia
Marietta, Georgia, United States, 30060
Newman, Georgia, United States, 30265
Stockbridge, Georgia, United States, 30281
United States, Louisiana
Shreveport, Louisiana, United States, 71105
United States, Minnesota
Saint Louis Park, Minnesota, United States, 55426
United States, Missouri
Kansas City, Missouri, United States, 64132
United States, Montana
Missoula, Montana, United States, 59802
United States, New Jersey
Berlin, New Jersey, United States, 08009
United States, North Carolina
Flat Rock, North Carolina, United States, 28731
Winston Salem, North Carolina, United States, 27103
United States, Ohio
Cleveland, Ohio, United States, 44110
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19146
United States, Texas
Bellaire, Texas, United States, 77401
Houston, Texas, United States, 77024
Houston, Texas, United States, 77089
United States, Utah
Salt Lake City, Utah, United States, 84124
United States, Virginia
Falls Church, Virginia, United States, 22042
Bruxelles, Belgium, 1000
Gabrovo, Bulgaria, 5300
Shumen, Bulgaria, 9700
Varna, Bulgaria, 9010
Czech Republic
Ceske Budejovice, Czech Republic, 370 01
Ceske Budejovice, Czech Republic, 370 87
Hradec Kralove, Czech Republic, 500 05
Most, Czech Republic, 434 64
Nova Ves pod Plesi 110, Czech Republic, 26 204
Ostrava-Poruba, Czech Republic, 708 52
Plzen, Czech Republic, 304 60
Bad Klosterlausnitz, Germany, 07639
Lunen, Germany, 44534
Wetlzlar, Germany, 35578
Deszk, Hungary, H-6772
Kecskemét, Hungary, H-6000
Komarom, Hungary, H-2900
Miskolc, Hungary, H-3501
Nyíregyháza, Hungary, H-4412
Szekszard, Hungary, H-7100
Rezekne, Latvia, LV-4600
Riga, Latvia, LV-1038
Klaipeda, Lithuania, LT-92288
Siauliai, Lithuania, LT-76307
Vilnius, Lithuania, LT-08660
Bialystok, Poland, 15-250
Bielsko-Biala, Slaskie, Poland, 43-300
Gliwice, Poland, 44-101
Poznan, Poland, 61-245
Warszawa, Poland, 02-781
Puerto Rico
Ponce, Puerto Rico, 00717
San Juan, Puerto Rico, 00927
Baia Mare, Romania, 430031
Braila, Romania, 810325
Bucuresti, Romania, 010976
Craiova, Romania, 200385
Oradea, Romania, 410469
Satu Mare, Romania, 440055
Suceava, Romania, 720237
United Kingdom
Bury St. Edmunds, United Kingdom, IP33 2QZ
Bury, United Kingdom, BL9 7TD
Edinburgh, United Kingdom, EH4 2XR
Glasgow, United Kingdom, G12 0YN
Manchester, United Kingdom, M8 5RB
Norwich, United Kingdom, NR4 7UY
Weston Super Mare, United Kingdom, BS23 4QT
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
GW Pharmaceuticals Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Responsible Party: GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT01262651     History of Changes
Other Study ID Numbers: GWCA0958
2009-016064-36 ( EudraCT Number )
First Posted: December 17, 2010    Key Record Dates
Last Update Posted: July 6, 2016
Last Verified: July 2016

Keywords provided by GW Pharmaceuticals Ltd.:
Cancer pain
Opioid therapy
Inadequate analgesia
Optimized chronic opioid therapy

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents